Detection of minimal residual disease in pediatric acute lymphoblastic leukemia
Version of Record online: 26 JUN 2013
Copyright © 2013 International Clinical Cytometry Society
Cytometry Part B: Clinical Cytometry
Volume 84, Issue 6, pages 359–369, November/December 2013
How to Cite
How to cite this article: Detection of Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia. Cytometry Part B 2013; 84B: 359–369., , , .
- Issue online: 25 OCT 2013
- Version of Record online: 26 JUN 2013
- Accepted manuscript online: 12 JUN 2013 02:25AM EST
- Manuscript Revised: 2 APR 2013
- Manuscript Accepted: 23 MAR 2013
- Manuscript Received: 31 OCT 2012
- Comitato M.L.Verga and Fondazione Tettamanti, Fondazione Città della Speranza, Fondazione Cariparo, Associazione Gian Franco Lupo, Associazione Italiana per la Ricerca sul Cancro, Fondazione Cariplo, and Ministero dell'Istruzione, Universita' e Ricerca (MIUR)
- 18International BFM Study Group (I-BFM-SG). Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008;22:771–782., , , , , , , , , , et al;
- 20Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: Report of the BIOMED-1 CONCERTED ACTION: Investigation of minimal residual disease in acute leukemia. Leukemia 1999;13:110–118., , , , , , , , , , et al.
- 44Benign hematogone-rich lymphoid proliferations can be distinguished from B-lineage acute lymphoblastic leukemia by integration of morphology, immunophenotype, adhesion molecule expression, and architectural features. Am J Clin Pathol 2000;114:66–75., , , Foucar K, Chong YY, Garner KW, Leith CP.
- 53BIOMED-I. BIOMED-I concerted action report: Flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation. Leukemia 2001;15:1185–1192., , , , , , , , , , et al;
- 65AIEOP-BFM-FCM-MRD-Study Group. Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: Predictive impact of early blast reduction on the remission status after induction. Leukemia 2009;23:528–534., , , , , , , , , ;
- 67UKALL Flow MRD Group; UK MRD steering Group. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting. Haematologica 2009;94:870–874., , , , , , , , , , et al;
- 78Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: The Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. J Clinical Oncol 2008;26:3046–3050., , , , , , , , , , et al.
- 85Australian and New Zealand Children's Oncology Group. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. Br J Haematol 2009;146:292–299., , , , , , , , , , et al;
- 87Japanese Childhood Cancer Leukemia Study Group. Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: A report from the Japanese Childhood Cancer and Leukemia Study Group. Pediatr Blood Cancer 2010;55:1287–1295., , , , , , , , , , et al;
- 98Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 2000;95790–794., , , , .
- 103Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time points reveals high levels of concordance between molecular and immunophenotypic approaches. Br J Haematol 2009;144:107–115., , , , , , , , , , et al.
- 108Assessment of clonal evolution at Ig/TCR loci in acute lymphoblastic leukaemia by single-strand conformation polymorphism studies and highly resolutive PCR derived methods: Implication for a general strategy of minimal residual disease detection. Br J Haematol 1995;90:85–93., , , , .
- 111Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: Implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection. Blood 2003;102:4520–4526., , , , , , , , .
- 115Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: Implications for residual disease detection: A report from the children's oncology group. Cytometry B Clin Cytom 2005;68B:18–24., , , , , .
- 116Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group. Cytometry B Clin Cytom 2010;78B:147–153., , , , , , , , , , et al.
- 118Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: A Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry. Br J Haematol 2011;152:743–753., , , , , , , , , , et al.